Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Wednesday said there is no association between administration of experimental weight loss drug MariTide and changes ...

Cantor Fitzgerald tells investors that MariTide’s Phase 1 data includes “a big surprise” as the supplemental appendix file ...

Amgen (AMGN) stock spiked after the company ruled out out bone density concerns linked to obesity drug MariTide, following a ...

Diabetes poses a significant risk to bone health, leading to decreased bone mineral density and increased fracture ...

Amgen said on Wednesday it does not see any bone safety concerns around the use of its experimental obesity drug, a day after ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...

Cantor analysts said they found the bone mineral density changes when reviewing supplemental data that was published along ...

CEO Bob Bradway said Amgen is "well advanced" in preparing to launch a Phase 3 testing round of MariTide in order to have ...

Amgen weighed in with its own statement on the data. “As previously stated, Amgen does not see an association between the ...